Skip to main content
Premium Trial:

Request an Annual Quote

PositiveID, SAIC Team Up in Pursuit of Defense Threat Reduction Contracts

NEW YORK (GenomeWeb News) – PositiveID today announced the signing of an agreement with Science Applications International Corporation aimed at pursuing defense threat reduction contracts.

Specifically, the two companies will go after the Defense Threat Reduction Agency Indefinite Delivery/Indefinite Quantity Multiple Award Contracts supporting the Weapons of Mass Destruction – Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic Research and Development/Survivability and Infrastructure programs.

The collaboration combines McLean, Va.-based SAIC's system engineering and integration capabilities with PositiveID's technologies for biothreat detection, PositiveID said. It added that it will offer its Dragonfly Rapid MD-x Cartridge-based diagnostic platform and Microfluidics-based Bioagent Networked Detector (M-BAND) airborne biothreat detector as part of the agreement.

DragonFly delivers molecular diagnostic results from a sample in less than 30 minutes and is being developed for the detection of radiation-induced cell damage in human bodies, influenza strains, and other pathogens and diseases, including E. coli, methicillin-resistant staphylococcus aureus, and human papillomavirus.

M-BAND is a bioaerosol monitor with integrated systems with sample collection, processing, and detection modules for the continuous analysis of air samples. According to Delray Beach, Fla.-based PositiveID, the system can detect bacteria, viruses, and toxins in as little as two hours.

Terms of the agreement were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.